NEW YORK - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in infectious disease treatments, has announced a milestone commercial sale of its antiviral medication TPOXX (tecovirimat ...

“At SIGA, we remain committed to expanding our global presence to ensure patients have access to TPOXX. We are proud to provide access to this antiviral therapy in Morocco as a potential ...

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered ...

(RTTNews) - Pharmaceutical company SIGA Technologies, Inc. (SIGA) announced Tuesday that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. This agreement marks SIGA's first ...

NEW YORK - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in infectious disease treatments, has announced a milestone commercial sale of its antiviral medication TPOXX (tecovirimat) to ...

Study authors said routine surveillance is needed to monitor for the emergence of drug resistance to safeguard the effectiveness of TPOXX, one of the few treatments approved for treatment of mpox.

CHICAGO (Reuters) - U.S. health officials have identified a cluster of cases caused by an mpox variant that are resistant to Siga Technologies' antiviral tecovirimat, branded as TPOXX, in five U.S ...